HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) shares dropped 5.7% on Friday . The stock traded as low as $15.06 and last traded at $15.22. Approximately 21,656 shares changed hands during trading, a decline of 80% from the average daily volume of 108,708 shares. The stock had previously closed at $16.13.
Analyst Ratings Changes
Separately, StockNews.com upgraded shares of HUTCHMED from a "hold" rating to a "buy" rating in a report on Friday.
Check Out Our Latest Analysis on HUTCHMED
HUTCHMED Stock Down 3.1 %
The firm has a fifty day simple moving average of $14.70 and a 200 day simple moving average of $16.48. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07.
Hedge Funds Weigh In On HUTCHMED
A number of hedge funds have recently made changes to their positions in the business. Connor Clark & Lunn Investment Management Ltd. increased its stake in HUTCHMED by 99.0% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 48,724 shares of the company's stock valued at $952,000 after acquiring an additional 24,245 shares during the period. Point72 Hong Kong Ltd bought a new stake in shares of HUTCHMED in the 3rd quarter valued at approximately $421,000. State Street Corp raised its holdings in shares of HUTCHMED by 0.9% in the 3rd quarter. State Street Corp now owns 349,524 shares of the company's stock worth $6,826,000 after buying an additional 3,078 shares in the last quarter. Jane Street Group LLC lifted its position in shares of HUTCHMED by 362.2% during the 3rd quarter. Jane Street Group LLC now owns 62,997 shares of the company's stock worth $1,305,000 after buying an additional 49,366 shares during the period. Finally, Public Employees Retirement System of Ohio acquired a new stake in HUTCHMED in the 3rd quarter valued at $35,000. Institutional investors and hedge funds own 8.82% of the company's stock.
HUTCHMED Company Profile
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Featured Articles
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
